Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Annals of Surgical Oncology

• Publication date

  2006-07-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/ASO.2006.03.069PMID 16865596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity

  2004cited by this paper
• Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

  2004cited by this paper
• Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.

  2004cited by this paper
• Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

  2002cited by this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cited by this paper
• Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

  2002cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Cancer vaccines targeting the HER2/neu oncogenic protein.

  2001cited by this paper
• Rapid degradation of a large fraction of newly synthesized proteins by proteasomes

  2000cited by this paper
• Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

  2000cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.

  2000cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

  1998cited by this paper
• Mechanisms of escape from CD8+ T‐cell clones specific for the HER‐2/NEU proto‐oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression

  1997cited by this paper
• Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

  1996cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

  1995cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

  1995cited by this paper
• HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

  1994cited by this paper
• In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

  1994cited by this paper
• Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.

  1993cited by this paper
• Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues

  1990cited by this paper
• The HLA System

  1990cited by this paper
• Distribution of HLA Antigens

  1990cited by this paper
• Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

  1990cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

  1985cited by this paper

• Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges

  2025cites this paper
• The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

  2024cites this paper
• The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study.

  2022cites this paper
• Breast Cancer Vaccines: Disappointing or Promising?

  2022cites this paper
• Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

  2021cites this paper
• Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

  2021cites this paper
• Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

  2020cites this paper
• The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients

  2020cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019influential citation
• The Impact of Anti-tumor Agents on ER-Positive MCF-7 and HER2-Positive SKBR-3 Breast Cancer Cells Biomechanics

  2019cites this paper
• Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.

  2019cites this paper
• Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

  2018cites this paper
• Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta‐analysis

  2018cites this paper
• The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives.

  2017cites this paper
• Evolution of anti-HER2 therapies for cancer treatment.

  2017cites this paper
• Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

  2017cites this paper
• Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model

  2017cites this paper
• Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

  2017cites this paper
• Anti-Tumour Treatment Evolution of anti-HER 2 therapies for cancer treatment

  2017cites this paper
• A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

  2016cites this paper
• Peptide Vaccination Strategies Targeting Commonly Shared Cancer Antigens

  2016cites this paper
• Peptide-Based Cancer Vaccine Strategies and Clinical Results.

  2016cites this paper
• Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

  2016cites this paper
• The development and use of the E75 (HER2 369-377) peptide vaccine.

  2016cites this paper
• A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice

  2016cites this paper
• Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

  2016cites this paper
• Adjuvant HER2/neu peptide cancer vaccines in breast cancer.

  2015cites this paper
• Cancer Neoantigens and Applications for Immunotherapy

  2015cites this paper
• New clinical advances in immunotherapy for the treatment of solid tumours

  2015cites this paper
• Breast Cancer Immunotherapy.

  2015cites this paper
• A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

  2014cites this paper
• Monoclonal antibodies therapies for ovarian cancer

  2013cites this paper
• Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines

  2013cites this paper
• New Insights into the Role of the Immune Microenvironment in Breast Carcinoma

  2013cites this paper
• Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab

  2013cites this paper
• Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

  2013cites this paper
• HER2/neu-specific Breast Cancer Vaccine

  2013cites this paper
• with Potent Antitumor Properties HLA-A*0201-Binding Epitope of HER-2/neu Identification of a Novel Immunogenic

  2013cites this paper
• Realizing the promise of breast cancer vaccines

  2012cites this paper
• Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

  2012cites this paper
• The GP2 peptide: A HER2/neu‐based breast cancer vaccine

  2012cites this paper
• Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice

  2011cites this paper
• New Insights into Human Epidermal Growth Factor Receptor 2 Blockade–What Agents and Combinations Work Best?

  2011cites this paper
• OT3-01-18: Combination Immunotherapy with Trastuzumab and the HER2 Vaccine E75 in Low and Intermediate HER2−Expressing Breast Cancer Patients To Prevent Recurrence.

  2011cites this paper
• Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy

  2011influential citation
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

  2011cites this paper
• [Anti-HER2 vaccines: The HER2 immunotargeting future?].

  2011cites this paper
• Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials

  2011cites this paper
• HER receptor-mediated dynamic signalling in breast cancer cells

  2011cites this paper
• The role of idiotype-specific immunity in antigen receptor diversity

  2010cites this paper
• A Degenerate Hla-dr Epitope Pool of Her-2/neu Reveals a Novel in Vivo Immunodominant Epitope, Her-2/neu 88-102 Nih Public Access Author Manuscript

  2010cites this paper
• Cancer Vaccines Targeting HER2/neu for Early Breast Cancer

  2010cites this paper
• Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients

  2010influential citation
• Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.

  2010cites this paper
• Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

  2010cites this paper
• Anti-HER2 vaccines: new prospects for breast cancer therapy

  2010cites this paper
• Cryotreatment as a simple method for cell preparation in autologous tumor cell-based vaccination.

  2010cites this paper
• A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102

  2010influential citation
• Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts

  2009cites this paper
• Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts Downregulation and Tumor Response in Athymic HER 2 Trastuzumab-Mediated In-DTPA-Pertuzumab Sensitively Detects 111 Micro-SPECT / CT with

  2009cites this paper
• Antibodies in cancer immunotherapy

  2009cites this paper
• Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

  2009cites this paper
• Pertuzumab Sensitively Detects Trastuzumab- Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA- MB-361 Human Breast Cancer Xenografts

  2009cites this paper
• The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2009cites this paper
• Récepteurs des lymphocytes t spécifiques de her2/neu

  2009cites this paper
• Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9

  2009cites this paper
• Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.

  2009cites this paper
• A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

  2009cites this paper
• Antibody-based cancer therapy

  2008cites this paper
• Potent Antitumor Properties neu HLA-A * 0201-Binding Epitope of HER-2 / Identification of a Novel Immunogenic

  2008cites this paper
• The E75 HER2/neu peptide vaccine

  2008influential citation
• Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2008cites this paper
• Immunotherapy with dendritic cells for cancer.

  2008cites this paper
• Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties1

  2008cites this paper
• Trastuzumab: mechanisms of resistance and therapeutic opportunities.

  2008cites this paper
• Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines

  2008cites this paper
• HER-2/neu Peptide Breast Cancer Vaccines: Current Status and Future Directions

  2007cites this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cites this paper
• Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy

  2007cites this paper
• HER2/neu Vaccines in Breast Cancer

  2006cites this paper